JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
Scope & Guideline
Pioneering research for a healthier cardiovascular future.
Introduction
Aims and Scopes
- Cardiovascular Drug Development:
The journal publishes studies investigating new pharmacological agents and their mechanisms of action in treating cardiovascular diseases, highlighting advancements in drug development. - Clinical Pharmacology and Therapeutics:
Research on the clinical application of cardiovascular drugs, including efficacy, safety, and pharmacokinetics, is central to the journal's scope. - Mechanisms of Cardiovascular Disease:
The journal explores the underlying biological mechanisms of cardiovascular diseases, providing insights into how various drugs can modify these pathways. - Personalized Medicine and Pharmacogenetics:
A focus on tailoring cardiovascular treatments based on genetic and phenotypic patient characteristics to optimize therapeutic outcomes. - Emerging Therapies and Innovations:
The publication highlights novel therapeutic approaches, including the use of biologics, gene therapy, and advanced drug delivery systems in cardiovascular care. - Interventional Cardiology:
Research on pharmacologic strategies during interventional procedures such as angioplasty and stenting, particularly concerning antiplatelet therapy and anticoagulation. - Cardiovascular Safety and Risk Management:
Studies addressing the safety profiles of cardiovascular drugs, including adverse effects, drug interactions, and risk factors associated with their use.
Trending and Emerging
- Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors:
Research on SGLT2 inhibitors has surged, emphasizing their role in heart failure management and cardiovascular protection beyond glucose control. - Antithrombotic Strategies and Dual Antiplatelet Therapy:
There is a growing emphasis on optimizing antithrombotic therapies, including novel approaches to dual antiplatelet therapy and their implications for various patient populations. - Biologics and Novel Therapeutics:
The journal increasingly features studies on biologics and new therapeutic modalities, reflecting a shift towards innovative treatment options in cardiovascular diseases. - Cardiovascular Outcomes in Diabetes Management:
Research on the cardiovascular implications of diabetes medications, particularly their effects on heart failure and other cardiovascular outcomes, is gaining prominence. - Regenerative Medicine and Stem Cell Therapy:
Emerging studies on the use of stem cells and regenerative medicine approaches to treat cardiovascular conditions are becoming a significant focus. - Pharmacogenomics in Cardiovascular Treatment:
The integration of pharmacogenomics into cardiovascular treatment strategies is increasingly prevalent, highlighting the importance of personalized medicine. - Impact of Inflammation on Cardiovascular Health:
Research exploring the role of inflammation in cardiovascular diseases and the potential therapeutic targets is trending, reflecting a growing understanding of pathophysiological mechanisms.
Declining or Waning
- Traditional Pharmacotherapies:
Research on established therapies, such as older anticoagulants and antiplatelet agents, appears to be waning as newer, more effective alternatives gain traction and clinical relevance. - Single-Agent Efficacy Studies:
There is a noticeable decline in studies focusing solely on the efficacy of single-agent therapies, as the field moves towards combination therapies and multi-target approaches. - Basic Science Studies Without Clinical Relevance:
Basic research studies that do not translate into clinical applications or implications are becoming less common, as the journal emphasizes translational research that impacts patient care. - Longitudinal Studies on Drug Safety:
Fewer longitudinal studies focusing on the long-term safety of cardiovascular drugs are being published, possibly due to a shift towards larger, multi-center trials that provide more comprehensive data.
Similar Journals
Cardiovascular Therapeutics
Unlocking Innovations in Cardiovascular MedicineCardiovascular Therapeutics is a renowned Open Access journal, published by WILEY-HINDAWI, that has been at the forefront of advancing knowledge in the field of cardiology and cardiovascular medicine since its establishment. With a strong commitment to disseminating high-quality research, the journal has successfully positioned itself within the Q2 quartile in multiple categories, including Cardiology and Cardiovascular Medicine, Medicine (miscellaneous), and Pharmacology. The journal is indexed in Scopus, achieving impressive rankings, such as #95 out of 387 in Cardiology, and #87 out of 272 in Medical Pharmacology. Situated in the United Kingdom, Cardiovascular Therapeutics embraces an Open Access model since 2019, ensuring that groundbreaking research is accessible to researchers, practitioners, and students across the globe. The journal is dedicated to publishing original research articles, reviews, and clinical studies that contribute to the understanding and treatment of cardiovascular diseases, making it an essential resource for those invested in improving patient outcomes and advancing therapeutic strategies in this vital area of medicine.
Netherlands Heart Journal
Transforming Cardiology Insights into Global Health SolutionsNetherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.
Cardiovascular Innovations and Applications
Bridging the gap between research and practice in cardiovascular medicine.Cardiovascular Innovations and Applications is a premier open-access journal dedicated to advancing knowledge in the field of cardiovascular medicine. Published by COMPUSCRIPT since 2016, this journal provides a platform for the dissemination of innovative research and applications that address crucial topics in cardiology, aiming to bridge the gap between clinical practice and cutting-edge research. With an ISSN of 2009-8618 and an E-ISSN of 2009-8782, it operates on a global scale, facilitating access to high-quality content without financial barriers. The journal is positioned within the Medicine - Cardiology and Cardiovascular Medicine category, and its current Scopus rank of #321/387 reflects its potential for growth and influence in the academic community, being in the 17th percentile. Researchers, healthcare professionals, and students will find Cardiovascular Innovations and Applications an invaluable resource in their quest for the latest findings and advancements in cardiovascular health and treatment methodologies.
Cardiology Journal
Elevating standards in heart health scholarship.Cardiology Journal, published by VIA MEDICA, stands as a prominent resource in the field of cardiology and cardiovascular medicine, with an ISSN of 1897-5593 and an E-ISSN of 1898-018X. Recognized for its Open Access model established since 1994, this journal facilitates widespread dissemination of critical research findings, allowing practitioners and researchers globally to access valuable insights without barriers. Based in Poland, with an address at UL SWIETOKRZYSKA 73, 80-180 GDANSK, it has achieved a respectable Q2 classification in 2023 for both Cardiology and Miscellaneous Medicine categories, reflecting its influence and quality within the scholarly community. With a Scopus ranking placing it at #117 out of 387 in Cardiology, it lies within the 69th percentile, underpinning its commitment to advancing knowledge in cardiovascular health. The journal’s converged years extending from 2006 to 2024 ensure it captures ongoing developments in a rapidly evolving field. As such, the Cardiology Journal serves as an indispensable platform for researchers, professionals, and students dedicated to exploring the frontiers of cardiac science and improving patient care.
Giornale Italiano di Cardiologia
Uniting Experts to Transform Heart HealthGiornale Italiano di Cardiologia is a premier journal in the field of cardiology, published by PENSIERO SCIENTIFICO EDITORE. Established in 1996, this journal serves as an essential platform for sharing the latest research and clinical advancements in cardiovascular medicine, particularly catering to the Italian and international medical communities. Although currently classified in the Q4 quartile for Cardiology and Cardiovascular Medicine (2023), the journal strives to enhance its impact and outreach by embracing rigorous peer-review practices and promoting high-quality submissions. With a commitment to enriching knowledge and fostering dialogue among researchers, clinicians, and students, the journal offers a collection of articles that include original research, reviews, and case studies. While currently not an Open Access publication, readers will benefit from a wealth of research insights that contribute to advancements in cardiac care and treatment strategies. As the Giornale Italiano di Cardiologia continues to evolve, it plays a vital role in bridging research and clinical practice in the cardiovascular domain.
CIRCULATION
Elevating Cardiology: Where Innovation Meets Excellence.CIRCULATION is a premier journal in the field of cardiology and cardiovascular medicine, published by Lippincott Williams & Wilkins. With a distinguished history dating back to 1950, the journal has consistently been at the forefront of critical research, showcasing significant advancements and discoveries in cardiovascular health. It holds a remarkable Q1 ranking in both the fields of Cardiology and Physiology (medical) according to the 2023 category quartiles, demonstrating its influential role among the top publications in these disciplines. With an impressive Scopus ranking, placed 3rd out of 387 in Cardiology and 2nd out of 113 in Physiology, CIRCULATION is essential reading for researchers, practitioners, and students passionate about advancing their understanding of heart health and related medical sciences. Although the journal is not open access, it continues to foster scholarly exchange and innovation in cardiovascular research, making it an indispensable resource for quality insights and groundbreaking studies.
Clinica e Investigacion en Arteriosclerosis
Fostering collaboration in cardiology and pharmacology advancements.Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.
Nepalese Heart Journal
Transforming Heart Health Through ResearchNepalese Heart Journal, published by the CARDIAC SOC NEPAL, serves as a premier platform for disseminating knowledge in the field of cardiology and cardiovascular health. With an ISSN of 2091-2978, this journal aims to bridge the gap between researchers, clinicians, and academicians by presenting high-quality, peer-reviewed articles that address clinical practices, innovative research, and emerging trends in heart disease management, especially within the context of Nepal and the surrounding region. Although it operates under a traditional publishing model, its commitment to excellence aids in reinforcing the scientific discourse in an area critical to public health. The journal is a valuable resource for professionals and students alike who are focused on advancing their understanding of cardiology and its implications for health policy and practice. Exploring the intersections of local challenges and global advancements in heart health, the Nepalese Heart Journal is poised to contribute meaningfully to the evolving landscape of cardiovascular research.
BRITISH JOURNAL OF PHARMACOLOGY
Advancing pharmacological science for a healthier tomorrow.British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.
European Journal of Preventive Cardiology
Championing excellence in preventive cardiology research.The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.